Effects of methylphenidate on response to oral levodopa: A double-blind clinical trial

Archives of Neurology

Volumn 64, Issue 3, 2007, Pages 319-323

  Nutt, John G ^a   Carter, Julie H ^a   Carlson, Nichole E ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; ENTACAPONE; LEVODOPA; METHYLPHENIDATE; PLACEBO;

ADULT; AGED; ANXIETY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG POTENTIATION; DRUG RESPONSE; DYSKINESIA; FEMALE; HEADACHE; HUMAN; HYPERGLYCEMIA; INSOMNIA; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PANIC; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; TREMOR; UNSPECIFIED SIDE EFFECT; URGE INCONTINENCE;

ADMINISTRATION, ORAL; AGED; ANTIPARKINSON AGENTS; CROSS-OVER STUDIES; DOPAMINE UPTAKE INHIBITORS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LEVODOPA; MALE; METHYLPHENIDATE; MIDDLE AGED; PARKINSON DISEASE; PSYCHOMOTOR PERFORMANCE; SEVERITY OF ILLNESS INDEX; TIME PERCEPTION; TREMOR; WALKING;

EID: 33947264639     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.64.3.319     Document Type: Article

References (21)

1. Cass WA, Zahniser NR, Flach KA, Gerhardt GA. Clearance of exogenous dopamine in rat striatum and nucleus accumbens: role of metabolism and effects of locally applied uptake inhibitors. J Neurochem. 1993;61:2269-2278.
2. Seibyl JP, Marek KL, Quinlan D, et al. Decreased single-photon emission computed tomographic [123-I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol. 1995;38:589-598.
3. Abercrombie ED, Bonatz AE, Zigmond MJ. Effects of L-DOPA on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Res. 1990;525:36-44.
4. Miller DW, Abercrombie ED. Role of high-affinity dopamine uptake and impulse activity in the appearance of extracellular dopamine in striatum after administration of exogenous L-DOPA: studies in intact and 6-hydroxydopamine- treated rats. J Neurochem. 1999;72:1516-1522.
5. Kuczenski R, Segal DS. Effects of methylphenidate on extracellular dopamine, serotonin and norepinephrine: comparison with amphetamine. J Neurochem. 1997;68:2032-2037.
6. Volkow ND, Wang G-J, Fowler JS, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry. 1998;155:1325-1331.
7. Booij J, Korn P, Linszen DH, van Royen EA. Assessment of endogenous dopamine release by methylphenidate challenge using iodine-123 iodobenzamide singlephoton emission tomography. Eur J Nucl Med. 1997;24:674-677.
8. Volkow ND, Wang G, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci. 2001;21:RC121.
9. Nutt JG, Carter JH, Sexton GJ. The dopamine transporter: importance in Parkinson's disease. Ann Neurol. 2004;55:766-773.
10. Patrick KS, Jarvi EJ. Capillary gas chromatographic-mass spectrometric analysis of plasma methylphenidate. J Chromatogr. 1990;528:214-221.
11. Nutt JG, Woodward WR, Carter JH. Clinical and biochemical studies with controlled-release levodopa/carbidopa. Neurology. 1986;36:1206-1211.
12. Camicioli R, Lea E, Nutt JG, Sexton G, Oken BS. Methylphenidate increases the motor effects of L-Dopa in Parkinson's disease: a pilot study. Clin Neuropharmacol. 2001;24:208-213.
13. Chouker M, Tatsch K, Linke R, Pogarell O, Hahn K, Schwarz J. Striatal dopamine transporter binding in early to moderately advanced Parkinson's disease: monitoring of disease progression over 2 years. Nucl Med Commun. 2001;22:721-725.
14. Eshuis SA, Maguire RP, Leenders KL, Jonkman S, Jager PL. Comparison of FPCIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson's disease. Eur J Nucl Med Mol Imaging. 2006;33:200-209.
15. Quinn D, Wigal S, Swanson J, et al. Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2004;43:1422-1429.
16. Lyseng-Williamson KA, Keating GM. Extended-release methylphenidate (Ritalin LA). Drugs. 2002;62:2251-2259.
17. Volkow ND, Fowler JS, Wang GJ, Ding YS, Gatley SJ. Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: results from imaging studies. Eur Neuropsychopharmacol. 2002;12:557-566.
18. Lee CS, Samii A, Sossi V, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol. 2000;47:493-503.
19. Koochesfahani KM, Fuente-Fernandez R, Sossi V, et al. Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients: positron emission tomographic studies. Mov Disord. 2006.
20. Frackiewicz EJ, Jhee SS, Shiovitz TM, et al. Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa. Ann Pharmacother. 2002;36:225-230.
21. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med. 2006;354:1445-1458.